![](https://investorshub.advfn.com/uicon/8777.png?cb=1703671008)
Saturday, June 21, 2014 12:49:52 AM
Would anyone care to illuminate and discuss the following? It seems to be comprehensive and rational.
Topics:
R&D
Isis is in the spotlight--and maybe crosshairs--after gene breakthrough
June 20, 2014 | By Damian Garde
Antisense specialist Isis Pharmaceuticals ($ISIS) has made it all the way to mid-stage trials with ISIS-APOCIIIRx, targeting patients with a rare ailment that leads to dangerously high triglycerides. But that candidate is looking all the more promising in light of two major studies linking its target to reduced rates of heart attack, saddling the biotech with a potential blockbuster.
Isis' drug inhibits the protein APOC3, which is tied for triglyceride metabolism in the blood. The company is in the midst of Phase II development in familial chylomicronemia syndrome (FCS), which the National Institutes of Health says affects about one in a million people, but the results of two New England Journal of Medicine studies may spur it to consider widening its plans.
Looking at patients with mutations that blunted their APOC3 genes, one group of NIH-funded researchers found a 40% reduction in triglyceride levels and, most promising, a 40% lower risk of heart disease. A second, unrelated study in Denmark produced "eerily consistent" results, one investigator told The New York Times. To date, cardio drugs have mostly targeted LDL, or "bad," cholesterol in hopes of improving heart function--including the new crop of expected-blockbuster PCSK9-blocking therapies--and the potential APOC3 pathway presents the biggest advance in years, researchers said.=
Now back to Isis. The biotech is suddenly sitting on a mid-stage candidate with activity against the industry's latest en-vogue target. Piper Jaffray analyst Joshua Schimmer told Bloomberg that an FCS approval alone could be worth $2 billion in sales, and the company could double that if it swung for a wider indication.
CEO Stanley Crooke said he's keeping his options open and his phone lines clear.
"We're weighing how we want to take full advantage of this breakthrough, and as we do that we have to consider the potential broader development of the follow on product," Crooke told Bloomberg. "We have a great deal of licensing interest for this drug."
But, thanks to its wide pipeline of gene-muting therapies and chronically underperforming stock, an acquirer might come along and force its hand, Schimmer said.
"At this valuation, it would be ripe for a hostile event," the analyst told Bloomberg.
Links to more comment in the original article:
http://www.fiercebiotech.com/story/isis-spotlight-and-maybe-crosshairs-after-gene-breakthrough/2014-06-20?utm_medium=rss&utm_source=rss&utm_campaign=rss
Recent IONS News
- Ionis announces olezarsen FCS New Drug Application accepted for Priority Review and enrollment in Phase 3 sHTG program completed • PR Newswire (US) • 06/25/2024 10:55:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/18/2024 01:29:02 PM
- Ionis announces expanded licensing agreement with Otsuka in Asia Pacific for investigational medicine donidalorsen in hereditary angioedema • PR Newswire (US) • 06/18/2024 11:00:00 AM
- Ionis to present at TD Cowen Genetic Medicines & RNA Summit • PR Newswire (US) • 06/17/2024 08:09:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 06/17/2024 02:59:16 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/10/2024 08:33:55 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/31/2024 11:15:31 AM
- Ionis presents positive results from OASIS-HAE and OASISplus studies of investigational medicine donidalorsen in patients with hereditary angioedema • PR Newswire (US) • 05/31/2024 11:00:00 AM
- Ionis to hold donidalorsen Phase 3 data webcast • PR Newswire (US) • 05/28/2024 11:00:00 AM
- New data from the Phase 3 NEURO-TTRansform study evaluating WAINUA™ (eplontersen) to be presented at the 2024 International Symposium on Amyloidosis (ISA) • PR Newswire (US) • 05/23/2024 11:00:00 AM
- Biogen and Ionis Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis • GlobeNewswire Inc. • 05/16/2024 11:30:14 AM
- Ionis and Biogen Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis • PR Newswire (US) • 05/16/2024 11:30:00 AM
- Ionis announces positive topline results from Phase 1/2a trial of ION582 for Angelman syndrome • PR Newswire (US) • 05/16/2024 11:00:00 AM
- Ionis to host 2024 virtual Annual Meeting of Stockholders • PR Newswire (US) • 05/15/2024 11:05:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/13/2024 09:25:49 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/07/2024 08:55:46 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/07/2024 07:55:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/07/2024 03:15:41 PM
- Ionis reports first quarter 2024 financial results • PR Newswire (US) • 05/07/2024 11:00:00 AM
- Ionis Publishes 2023 Corporate Responsibility Report • PR Newswire (US) • 04/25/2024 11:00:00 AM
- Ionis to hold first quarter 2024 financial results webcast • PR Newswire (US) • 04/23/2024 11:05:00 AM
- Ionis presents positive results from Phase 3 Balance study of olezarsen for familial chylomicronemia syndrome • PR Newswire (US) • 04/07/2024 01:48:00 PM
- Ionis to present at upcoming investor conferences • PR Newswire (US) • 04/01/2024 11:05:00 AM
- Ionis to hold olezarsen Phase 3 data webcast • PR Newswire (US) • 03/28/2024 11:05:00 AM
- Positive olezarsen Phase 3 data in familial chylomicronemia syndrome to be presented at 2024 American College of Cardiology (ACC) annual meeting • PR Newswire (US) • 03/25/2024 12:18:00 PM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM